Is dual immunotherapy needed in first-line treatment of microsatellite instability (MSI)-high metastatic colorectal cancer?

Ann Palliat Med. 2023 Mar;12(2):427-430. doi: 10.21037/apm-22-1426. Epub 2023 Jan 15.
No abstract available

Keywords: Immunotherapy; colorectal cancer (CRC); ipilimumab; microsatellite instability (MSI); nivolumab.

MeSH terms

  • Colonic Neoplasms*
  • Colorectal Neoplasms* / pathology
  • Humans
  • Immunotherapy
  • Microsatellite Instability